Novo Nordisk Shares Plunge 21% As Ozempic Are Sales Expected To Slow

Forbes

Read the full story on Forbes: https://www.forbes.com/sites/tylerroush/2025/07/29/novo-nordisk-shares-plunge-21-toward-worst-day-in-40-years-as-ozempic-sales-expected-to-slow/  Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1  Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:  https://account.forbes.com/membership/?utm_source=youtube&utm_medium=display&utm_campaign=growth_non-sub_paid_subscribe_ytdescript  Stay Connected Forbes newsletters: https://newsletters.editorial.forbes.com Forbes on Facebook: http://fb.com/forbes Forbes Video on Twitter: http://www.twitter.com/forbes Forbes Video on Instagram: http://instagram.com/forbes More From Forbes:  http://forbes.com  Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

Transcript

00:00Shares of Novo Nordisk, the company which manufactures popular weight-loss drugs Wegovy and Ozempic,

00:06experienced one of its worst days in almost 40 years.

00:10Shares of Novo Nordisk plunged more than 21% around 10.50 a.m. Eastern

00:15after the company said its expectations for full-year sales and profit growth were lowered.

00:22The healthcare company attributed a potential decline in sales of its weight-loss drugs

00:26to the persistent use of compounded alternatives.

00:30Compounded drugs are generic drugs which are altered to meet a patient's need

00:34and are not approved by the Food and Drug Administration.

00:38The pharmaceutical firm said Tuesday expectations for its full-year sales growth in 2025

00:44were lowered to between 8% to 14%, down from an earlier target of 13% to 21%,

00:51and profit growth lowered to between 10% to 16%, down from estimates of 16% to 24%.

00:59The company has been struggling with the issue of compounded Ozempic and Wegovy for a while,

01:04and its shares have dropped 37% on the year.

01:09Novo Nordisk claims that even though the FDA has taken action against the distribution of

01:14quote-unquote unsafe and unlawful drugs, the sale of these compounded drugs has continued.

01:19The company also said that this poses patients being exposed to the risks of knockoff drugs.

01:27The FDA previously allowed the sale of copies of both Wegovy and Ozempic amid shortages of Novo Nordisk's weight-loss drugs,

01:35which it has since declared resolved.

01:37The company claims that the sale of alternatives continues on the market,

01:42and has asked the FDA to ban compounded Wegovy and Ozempic.

01:47On August 6th, Novo Nordisk will be releasing its Q2 earnings report.

01:52For more on this story, check out the article linked in the description.

Category

Transcript

Recommended